PLx Pharma Stock Forecast, Price & News

+0.33 (+1.83 %)
(As of 08/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume619,809 shs
Average Volume376,161 shs
Market Capitalization$420.48 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PLXP News and Ratings via Email

Sign-up to receive the latest news and ratings for PLx Pharma and its competitors with MarketBeat's FREE daily newsletter.

PLx Pharma logo

About PLx Pharma

PLx Pharma Inc., a specialty pharmaceutical company, focuses on developing the PLxGuard drug delivery system to provide various products in the United States. The company's lead product candidates are Vazalore 325 mg and Vazalore 81 mg, which are formulations of aspirin that use the PLxGuard delivery system, which provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable, and predictable platelet inhibition as compared to enteric-coated aspirin, as well as reduces the risk of stomach erosions and ulcers as compared with immediate-release aspirin, after seven days of treatment. Its product pipeline also includes other oral nonsteroidal anti-inflammatory drugs using the PLxGuard drug delivery system, such as PL1200 Ibuprofen 200 mg and PL1200 Ibuprofen 400 mg, which are in Phase I clinical stage for pain and inflammation, as well as PL1100 Ibuprofen 400 mg. PLx Pharma Inc. was founded in 2002 and is headquartered in Sparta, New Jersey.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.72 out of 5 stars

Medical Sector

824th out of 1,309 stocks

Pharmaceutical Preparations Industry

407th out of 646 stocks

Analyst Opinion: 2.3Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

PLx Pharma (NASDAQ:PLXP) Frequently Asked Questions

Is PLx Pharma a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PLx Pharma in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PLx Pharma stock.
View analyst ratings for PLx Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than PLx Pharma?

Wall Street analysts have given PLx Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but PLx Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting PLx Pharma?

PLx Pharma saw a increase in short interest in July. As of July 15th, there was short interest totaling 1,480,000 shares, an increase of 24.4% from the June 30th total of 1,190,000 shares. Based on an average daily volume of 469,200 shares, the days-to-cover ratio is currently 3.2 days. Approximately 7.9% of the shares of the company are short sold.
View PLx Pharma's Short Interest

When is PLx Pharma's next earnings date?

PLx Pharma is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for PLx Pharma

How can I listen to PLx Pharma's earnings call?

PLx Pharma will be holding an earnings conference call on Friday, August 6th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "8277376".

How were PLx Pharma's earnings last quarter?

PLx Pharma Inc. (NASDAQ:PLXP) released its quarterly earnings results on Friday, May, 14th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.56.
View PLx Pharma's earnings history

How has PLx Pharma's stock been impacted by Coronavirus (COVID-19)?

PLx Pharma's stock was trading at $4.81 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PLXP shares have increased by 282.7% and is now trading at $18.41.
View which stocks have been most impacted by COVID-19

What price target have analysts set for PLXP?

3 brokers have issued 1 year price objectives for PLx Pharma's shares. Their forecasts range from $21.00 to $22.00. On average, they expect PLx Pharma's stock price to reach $21.50 in the next twelve months. This suggests a possible upside of 16.8% from the stock's current price.
View analysts' price targets for PLx Pharma
or view top-rated stocks among Wall Street analysts.

Who are PLx Pharma's key executives?

PLx Pharma's management team includes the following people:
  • Mr. Michael J. Valentino, Exec. Chairman (Age 67, Pay $406.25k)
  • Ms. Natasha Giordano, CEO, Pres & Director (Age 61, Pay $912.33k)
  • Ms. Rita M. O'Connor CPA, CPA, CFO and Head of Manufacturing & Supply Chain (Age 53, Pay $638.12k)
  • Mr. Ronald R. Zimmerman, Founder & Sr. Advisor (Age 68)
  • Mr. Tom Long, VP of Manufacturing & Technical Operations
  • Ms. Joanne Cotignola, VP of Marketing
  • Mr. Patrick M. Lonergan, Member of Chief Exec. Officer Advisory Group (Age 86)
  • Mr. Charles Edmund Sheedy C.F.A., CFA, Member of Chief Exec. Officer Advisory Group (Age 74)
  • Mr. Harris Kaplan MBA, Member of Chief Exec. Officer Advisory Group (Age 69)
  • Mr. Gary L. Mossman, Sr. Advisor (Age 80)

Who are some of PLx Pharma's key competitors?

What other stocks do shareholders of PLx Pharma own?

When did PLx Pharma IPO?

(PLXP) raised $68 million in an IPO on Thursday, February 4th 2016. The company issued 3,800,000 shares at a price of $17.00-$19.00 per share. Raymond James acted as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.

What is PLx Pharma's stock symbol?

PLx Pharma trades on the NASDAQ under the ticker symbol "PLXP."

Who are PLx Pharma's major shareholders?

PLx Pharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Eidelman Virant Capital (0.08%). Company insiders that own PLx Pharma stock include John Hadden, Michael J Valentino and Rita M O'connor.
View institutional ownership trends for PLx Pharma

Which major investors are buying PLx Pharma stock?

PLXP stock was bought by a variety of institutional investors in the last quarter, including Eidelman Virant Capital. Company insiders that have bought PLx Pharma stock in the last two years include John Hadden, Michael J Valentino, and Rita M O'connor.
View insider buying and selling activity for PLx Pharma
or or view top insider-buying stocks.

How do I buy shares of PLx Pharma?

Shares of PLXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PLx Pharma's stock price today?

One share of PLXP stock can currently be purchased for approximately $18.41.

How much money does PLx Pharma make?

PLx Pharma has a market capitalization of $420.48 million and generates $30,000.00 in revenue each year. The biotechnology company earns $-15,210,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis.

How many employees does PLx Pharma have?

PLx Pharma employs 8 workers across the globe.

What is PLx Pharma's official website?

The official website for PLx Pharma is

Where are PLx Pharma's headquarters?

PLx Pharma is headquartered at 9 Fishers Lane Suite E, Sparta NJ, 07871.

How can I contact PLx Pharma?

PLx Pharma's mailing address is 9 Fishers Lane Suite E, Sparta NJ, 07871. The biotechnology company can be reached via phone at 973-409-6541 or via email at [email protected]

This page was last updated on 8/3/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.